Hoth Therapeutics, Inc. (HOTH)
NASDAQ: HOTH · Real-Time Price · USD
0.7432
+0.0461 (6.61%)
At close: Apr 16, 2026, 4:00 PM EDT
0.6817
-0.0615 (-8.28%)
After-hours: Apr 16, 2026, 7:58 PM EDT
Hoth Therapeutics Employees
As of December 31, 2025, Hoth Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,156,434
Market Cap
14.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 3 | 0 | - | 2 | 1 |
| Dec 31, 2024 | 3 | 0 | - | 2 | 1 |
| Dec 31, 2023 | 3 | 0 | - | 2 | 1 |
| Dec 31, 2022 | 3 | -2 | -40.00% | 2 | 1 |
| Dec 31, 2021 | 5 | 1 | 25.00% | 4 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Imunon | 25 |
| BioCardia | 21 |
| Moleculin Biotech | 17 |
| IN8bio | 17 |
| Cellectar Biosciences | 11 |
| Intensity Therapeutics | 7 |
| Jupiter Neurosciences | 5 |
| Kairos Pharma | 4 |
HOTH News
- 2 days ago - Move Over Novo Nordisk - This Small Company Study Flags Edge In Fatty Liver Drug - Benzinga
- 2 days ago - Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide - PRNewsWire
- 14 days ago - Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering - PRNewsWire
- 15 days ago - Hoth Therapeutics Announces $2.0 Million Registered Direct Offering - PRNewsWire
- 15 days ago - Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six - PRNewsWire
- 16 days ago - Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology - PRNewsWire
- 21 days ago - Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery - PRNewsWire
- 23 days ago - Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption - PRNewsWire